Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094653
Status:
COMPLETED
Last Update Posted:
2011-07-11
First Post:
2004-10-21
Brief Title:
MDX-010 Antibody MDX-1379 Melanoma Vaccine or MDX-010MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Organization Data
Organization:
Bristol-Myers Squibb
Class:
INDUSTRY
Study ID:
MDX010-20
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Bristol-Myers Squibb
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Study Director
Old Organization:
Bristol-Myers Squibb